-
1
-
-
84903158141
-
Extracorporeal membrane oxygenation in cardiopulmonary disease in adults
-
Abrams D, Combes A, Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol. 2014;63(25):2769-2778.
-
(2014)
J am Coll Cardiol
, vol.63
, Issue.25
, pp. 2769-2778
-
-
Abrams, D.1
Combes, A.2
Brodie, D.3
-
2
-
-
67650391955
-
And the winner is: Regional citrate anticoagulation
-
Bouman CS. And the winner is: regional citrate anticoagulation. Crit Care Med. 2009;37(2):764-765.
-
(2009)
Crit Care Med
, vol.37
, Issue.2
, pp. 764-765
-
-
Bouman, C.S.1
-
3
-
-
0021265581
-
Pharmacological studies of FUT- 175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments
-
Aoyama T, I no Y, Ozeki M, et al. Pharmacological studies of FUT- 175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol. 1984;35(3): 203-227.
-
(1984)
Jpn J Pharmacol
, vol.35
, Issue.3
, pp. 203-227
-
-
Aoyama, T.1
No, Y.2
Ozeki, M.3
-
4
-
-
0022177378
-
Analysis of complement activation profile during cardiopulmonary bypass and its inhibition by FUT-175
-
Miyamoto Y, Hirose H, Matsuda H, et al. Analysis of complement activation profile during cardiopulmonary bypass and its inhibition by FUT-175. Trans Am Soc Artif Intern Organs. 1985;31:508-511.
-
(1985)
Trans am Soc Artif Intern Organs
, vol.31
, pp. 508-511
-
-
Miyamoto, Y.1
Hirose, H.2
Matsuda, H.3
-
5
-
-
84907847994
-
-
Lee YK, Lee HW, Choi KH, Kim BS. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS One. 2014;9(10):e108737.
-
-
-
Lee, Y.K.1
Lee, H.W.2
Choi, K.H.3
Kim, B.S.4
-
6
-
-
84863239727
-
The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding
-
Baek NN, Jang HR, Huh W, et al. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail. 2012;34(3):279-285.
-
(2012)
Ren Fail
, vol.34
, Issue.3
, pp. 279-285
-
-
Baek, N.N.1
Jang, H.R.2
Huh, W.3
-
7
-
-
79961087823
-
Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: A three-year retrospective cohort study
-
Maruyama Y, Yoshida H, Uchino S, et al. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study. Int J Artif Organs. 2011;34(7):571-576.
-
(2011)
Int J Artif Organs
, vol.34
, Issue.7
, pp. 571-576
-
-
Maruyama, Y.1
Yoshida, H.2
Uchino, S.3
-
8
-
-
84891428990
-
Nafamostat mesilate: Can it be used as a conduit preserving agent in coronary artery bypass surgery
-
Yoon YS, Oh H, Kim Y, Lim SP, Kim CS, Kang MW. Nafamostat mesilate: can it be used as a conduit preserving agent in coronary artery bypass surgery? Korean J Thorac Cardiovasc Surg. 2013;46(6):413-425.
-
(2013)
Korean J Thorac Cardiovasc Surg
, vol.46
, Issue.6
, pp. 413-425
-
-
Yoon, Y.S.1
Oh, H.2
Kim, Y.3
Lim, S.P.4
Kim, C.S.5
Kang, M.W.6
-
9
-
-
79960148135
-
Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation
-
Han SJ, Kim HS, Kim KI, et al. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. J Korean Med Sci. 2011;26(7):945-950.
-
(2011)
J Korean Med Sci
, vol.26
, Issue.7
, pp. 945-950
-
-
Han, S.J.1
Kim, H.S.2
Kim, K.I.3
-
10
-
-
0030953579
-
Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygen- ation—a preliminary report
-
Nagaya M, Futamura M, Kato J, Niimi N, Fukuta S. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygen- ation—a preliminary report. J Pediatr Surg. 1997;32(4):531-535.
-
(1997)
J Pediatr Surg
, vol.32
, Issue.4
, pp. 531-535
-
-
Nagaya, M.1
Futamura, M.2
Kato, J.3
Niimi, N.4
Fukuta, S.5
-
11
-
-
0035109624
-
Extracorporeal membrane oxygenation for newborns with gastric rupture
-
Nagaya M, Kato J, Niimi N, Tanaka S. Extracorporeal membrane oxygenation for newborns with gastric rupture. Pediatr Surg Int. 2001;17(1):35-38.
-
(2001)
Pediatr Surg Int
, vol.17
, Issue.1
, pp. 35-38
-
-
Nagaya, M.1
Kato, J.2
Niimi, N.3
Tanaka, S.4
-
12
-
-
0019817468
-
New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin
-
Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. 1981;661(2):342-345.
-
(1981)
Biochim Biophys Acta
, vol.661
, Issue.2
, pp. 342-345
-
-
Fujii, S.1
Hitomi, Y.2
-
13
-
-
0029614808
-
Mechanisms of hyperkalemia caused by nafamostat mesilate
-
Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesilate. Gen Pharmacol. 1995;26(8):1627-1632.
-
(1995)
Gen Pharmacol
, vol.26
, Issue.8
, pp. 1627-1632
-
-
Muto, S.1
Imai, M.2
Asano, Y.3
-
14
-
-
0028950164
-
Hyperkalemia due to nafamostat mesylate
-
Kitagawa H, Chang H, Fujita T. Hyperkalemia due to nafamostat mesylate. N Engl J Med. 1995;332(10):687.
-
(1995)
N Engl J Med
, vol.332
, Issue.10
, pp. 687
-
-
Kitagawa, H.1
Chang, H.2
Fujita, T.3
|